US Patent

US8907099 — Nitrocatechol derivatives as COMT inhibitors

Composition of Matter · Assigned to Bial Portela and Cia SA · Expires 2027-05-12 · 1y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects new compounds of formula I, which have potentially valuable pharmaceutical properties as COMT inhibitors.

USPTO Abstract

New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

Drugs covered by this patent

Patent Metadata

Patent number: US8907099
Jurisdiction: US
Classification: Composition of Matter
Expires: 2027-05-12
Drug substance claim: Yes
Drug product claim: No
Assignee: Bial Portela and Cia SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.